US 11,986,503 B2
Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy
Liang Deng, New York, NY (US); Stewart Shuman, New York, NY (US); Jedd Wolchok, New York, NY (US); Taha Merghoub, New York, NY (US); Weiyi Wang, New York, NY (US); Peihong Dai, New York, NY (US); and Ning Yang, New York, NY (US)
Assigned to Memorial Sloan Kettering Cancer Center, New York, NY (US)
Filed by MEMORIAL SLOAN KETTERING CANCER CENTER, New York, NY (US)
Filed on Dec. 21, 2022, as Appl. No. 18/086,594.
Application 18/086,594 is a continuation of application No. 16/988,137, filed on Aug. 7, 2020, granted, now 11,541,087.
Application 16/988,137 is a continuation of application No. 16/673,475, filed on Nov. 4, 2019, granted, now 10,765,711.
Application 16/673,475 is a continuation of application No. 16/079,217, granted, now 10,512,662, previously published as PCT/US2017/019548, filed on Feb. 25, 2017.
Claims priority of provisional application 62/300,066, filed on Feb. 25, 2016.
Prior Publication US 2023/0310526 A1, Oct. 5, 2023
Int. Cl. A61P 35/00 (2006.01); A61K 35/76 (2015.01); A61K 35/768 (2015.01); A61K 39/395 (2006.01); A61K 48/00 (2006.01); A61P 37/04 (2006.01); C07K 14/52 (2006.01); C07K 14/535 (2006.01); C07K 16/28 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); A61K 39/00 (2006.01)
CPC A61K 35/768 (2013.01) [A61K 35/76 (2013.01); A61K 39/3955 (2013.01); A61K 48/00 (2013.01); A61P 35/00 (2018.01); C07K 14/521 (2013.01); C07K 14/535 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C12N 15/86 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C12N 2710/24121 (2013.01); C12N 2710/24132 (2013.01); C12N 2710/24133 (2013.01); C12N 2710/24143 (2013.01); C12N 2710/24161 (2013.01)] 14 Claims
 
1. A kit comprising a composition comprising a recombinant vaccinia virus selected from the group consisting of: (i) E3LΔ83N-TK−-hFlt3L; (ii) E3LΔ83N-TK−; (iii) E3LΔ83N-TK−-GM-CSF; and (iv) combinations thereof in replicative or inactivated form.